CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal and gastroesophageal cancers.
  
  LEARNING OBJECTIVES

  • Develop a long-term care plan for individuals diagnosed with metastatic colorectal cancer (mCRC), considering biomarker profile (MSI, HER2), tumor location, prior systemic therapy, symptomatology, performance status and personal goals of treatment.
  • Evaluate available data with anti-PD-1 and anti-CTLA-4 antibodies for microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) mCRC, and appropriately integrate these agents into personalized care plans for patients.
  • Describe ongoing research to validate the potential benefit of immune checkpoint inhibitors in combination with chemotherapy, targeted therapy or other immunotherapies for patients with MSI-H/dMMR or microsatellite-stable mCRC, and use this information to guide trial design and patient referral.
  • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to individualize the selection and sequence of systemic therapy for locally advanced or metastatic gastric or gastroesophageal cancer.
  • Describe the published research data with and ongoing evaluation of immune checkpoint inhibitors in the management of gastric, gastroesophageal junction and esophageal cancers, and identify patients who may be eligible for this strategy as part of a clinical research study or outside of a protocol setting.
  • Recall the biologic rationale for and available data with the use of trastuzumab deruxtecan for patients with previously treated HER2-positive CRC or gastric/gastroesophageal cancer, and discern the current and potential clinical applicability of this strategy.
  • Devise a rational approach to the incorporation of TAS-102 into the treatment algorithms for previously treated locally advanced or metastatic CRC or gastric/gastroesophageal cancer.
  • Identify ongoing clinical trials evaluating novel agents and strategies for CRC and gastroesophageal cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Peter C Enzinger, MD
  Director, Center for Esophageal and Gastric Cancer
  Dana-Farber/Brigham and Women’s Cancer Center
  Institute Physician, Dana-Farber Cancer Institute
  Associate Professor, Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Taiho Oncology Inc, Takeda Oncology, Zymeworks.
  
  Zev Wainberg, MD, MSc
  Co-Director, GI Oncology Program
  Director of Early Phase Clinical Research
  Jonsson Comprehensive Cancer Center
  UCLA School of Medicine
  Los Angeles, California
  
  Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Molecular Templates; Contracted Research: Arcus Biosciences, Five Prime Therapeutics Inc, Novartis, Plexxikon Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Pfizer Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Sumitomo Dainippon Pharma Oncology Inc and Taiho Oncology Inc.
  
  Release date: February 2021
  Expiration date: February 2022